Loading field map
Tumor immunology is the branch of immunology that studies the relationships between the immune system and cancer. Its central questions are deceptively simple: Why do cancers so often evade or suppress immune responses that ought to destroy them? How do immune cells recognize—or fail to recognize—malignant cells as abnormal? And can the immune system be deliberately redirected or unleashed to treat established tumors? The field sits at the intersection of two large bodies of knowledge: the cellular and molecular machinery of immunity, and the biology of malignant transformation, tumor progression, and metastasis.
To understand tumor immunology, one must first grasp a basic tension. The immune system evolved primarily to detect and eliminate infectious pathogens, and it does so through two broad arms. The innate immune system acts quickly and nonspecifically, recognizing molecular patterns common to many microbes. The adaptive immune system is slower but exquisitely specific: T cells and B cells carry receptors generated by gene rearrangement, allowing them to recognize virtually any molecular shape, including antigens not encountered before. Cancer cells, however, are not foreign invaders. They are transformed versions of the body's own cells, carrying mutated proteins, aberrantly expressed normal proteins, or viral proteins in the case of some cancers. The immune system must therefore distinguish "altered self" from "normal self"—a task complicated by the fact that the immune system is actively trained to tolerate self-antigens.
This tension gives rise to the field's organizing concept: immunoediting. The idea, which crystallized in the early 2000s from decades of animal experiments, holds that the immune system and tumors engage in a dynamic, three-phase process. In the elimination phase, immune cells—particularly natural killer (NK) cells and cytotoxic T lymphocytes—recognize and destroy malignant cells, potentially eradicating the tumor before it becomes clinically apparent. In the equilibrium phase, some tumor cells survive but are held in check, their growth restrained by ongoing immune pressure. In the escape phase, tumor cells that have acquired mutations or epigenetic changes allowing them to resist immune attack begin to grow progressively, producing a clinically detectable cancer. This framework replaced an older, simpler debate about whether the immune system even surveilled tumors at all, and it remains the standard way of describing the field's core problem.
The idea that the immune system might fight cancer is nearly as old as immunology itself. In the late nineteenth century, the New York surgeon William Coley injected bacterial toxins into tumors, hoping to provoke an immune response that would destroy the malignancy. His results were inconsistent and his mechanism obscure, and the approach was largely abandoned with the rise of radiation and chemotherapy. For much of the twentieth century, tumor immunology was a marginal pursuit, hampered by the difficulty of distinguishing true tumor-specific immune responses from the general inflammation that accompanies any growing mass.
Two developments in the mid-twentieth century gave the field firmer footing. First, the discovery of inbred mouse strains allowed researchers to transplant tumors between genetically identical animals, demonstrating that mice could be immunized against transplanted tumors—that is, a mouse that had rejected one tumor would rapidly reject a second transplant of the same tumor. This established that tumors carried antigens recognizable by the immune system. Second, the elucidation of the major histocompatibility complex (MHC)—the molecules that present peptide fragments to T cells—revealed the mechanism by which T cells could see intracellular proteins. A tumor cell's mutated proteins could be processed into peptides, loaded onto MHC molecules, and displayed on the cell surface, where a T cell with the right receptor could recognize them.
The modern era of tumor immunology began in the 1990s with the cloning of the first human tumor antigens—proteins recognized by T cells from cancer patients. This opened the door to cancer vaccines and adoptive cell therapies, though early clinical trials were largely disappointing. The field's transformation into a central pillar of cancer medicine came with the development of immune checkpoint inhibitors in the 2010s. These drugs, which block inhibitory receptors on T cells, produced durable responses in a subset of patients with previously untreatable metastatic cancers, definitively proving that the immune system could be harnessed to fight cancer in humans.
Tumor immunology is not organized around a single paradigm but rather around several complementary approaches that address different aspects of the tumor-immune interaction. These approaches coexist, overlap, and increasingly inform one another.
The immunoediting framework, described above, is the field's overarching conceptual model. It grew out of experiments showing that mice lacking certain immune components—particularly the cytokine interferon-gamma or the adaptive immune system entirely—developed more chemically induced and spontaneous tumors than immunocompetent mice, and that tumors arising in immunodeficient mice were more immunogenic when transplanted into normal mice. This demonstrated that the immune system not only protects against cancer but also shapes the immunogenicity of tumors that do arise, selecting for less immunogenic variants. The framework's importance lies in its insistence that the immune system's relationship to cancer is bidirectional and dynamic, not simply protective or simply harmful.
A major strand of the field is devoted to identifying and characterizing the antigens that T cells recognize on tumors. These fall into several categories. Mutated antigens, or neoantigens, arise from somatic mutations in tumor DNA and are truly tumor-specific; they are not expressed by normal tissues. Cancer-germline antigens are normal proteins expressed only in the germline and placenta, which are immunologically privileged sites, but are aberrantly reactivated in many tumors. Differentiation antigens are normal proteins expressed by the tissue of origin—for example, melanocyte proteins in melanoma—and are also expressed by normal cells, meaning T cells against them must overcome self-tolerance. Viral antigens are relevant in the subset of cancers caused by oncogenic viruses such as human papillomavirus and Epstein-Barr virus.
The distinction matters clinically. Neoantigens are the most tumor-specific and are thought to be the primary targets of many successful immunotherapies, but they are unique to each patient's tumor, making them difficult to target with off-the-shelf approaches. Differentiation antigens are shared across patients but carry the risk of autoimmune attack on normal tissues. This strand of the field is fundamentally about molecular identification: what, exactly, does the immune system see when it looks at a tumor?
A third approach focuses not on the tumor cell itself but on the ecosystem in which it grows. The tumor microenvironment includes stromal cells, blood vessels, and a complex infiltrate of immune cells—T cells, B cells, macrophages, myeloid-derived suppressor cells, and regulatory T cells. The composition of this infiltrate is strongly prognostic in many cancers: patients whose tumors contain many cytotoxic T cells tend to do better, while those with abundant immunosuppressive cells tend to do worse.
The key insight from this work is that tumors are not passive targets of immune attack but active architects of their own immune privilege. They secrete immunosuppressive cytokines such as transforming growth factor-beta and interleukin-10; they recruit regulatory T cells and myeloid-derived suppressor cells that inhibit effector T cells; they upregulate ligands that engage inhibitory receptors on T cells; and they create a metabolic environment—low oxygen, low glucose, high lactate—that impairs T cell function. The tumor microenvironment is thus a battleground, and much of modern tumor immunology is devoted to understanding how the balance of activating and suppressive signals is struck, and how it might be tipped in favor of immunity.
The most clinically consequential approach to emerge in recent decades is the study of immune checkpoints—inhibitory receptors on T cells that normally serve to limit immune responses and prevent autoimmunity. The two most important are CTLA-4, which competes with the costimulatory receptor CD28 for binding to B7 molecules on antigen-presenting cells, and PD-1, which binds to PD-L1 and PD-L2 ligands expressed on tumor cells and stromal cells. When engaged, these receptors dampen T cell activation, proliferation, and effector function.
The therapeutic insight was that tumors exploit these checkpoints to turn off the very T cells that might destroy them. Antibodies that block CTLA-4 or PD-1 can therefore "release the brakes" on antitumor T cells, allowing them to mount effective responses. This approach, called checkpoint blockade, has transformed the treatment of melanoma, lung cancer, kidney cancer, and several other malignancies. It is important to understand, however, that checkpoint blockade does not create immunity where none exists; it amplifies pre-existing antitumor T cell responses. This explains why patients whose tumors already contain T cells—so-called inflamed or hot tumors—respond better than those whose tumors are immunologically cold.
A fifth approach takes the opposite strategy: rather than trying to mobilize the patient's existing immune response, it engineers immunity from scratch. Adoptive cell therapy involves harvesting T cells from a patient, selecting or engineering those with antitumor specificity, expanding them to large numbers in the laboratory, and infusing them back into the patient. The most successful form is CAR T cell therapy, in which T cells are genetically modified to express a chimeric antigen receptor—a synthetic molecule that combines an antibody's antigen-binding domain with T cell signaling domains. This allows the T cells to recognize cell-surface proteins on tumors without needing MHC presentation.
CAR T cell therapy has been dramatically effective in certain B cell malignancies, such as acute lymphoblastic leukemia and large B cell lymphoma, where the target antigen CD19 is uniformly expressed on malignant cells. Its limitations are equally instructive: it has been less effective in solid tumors, partly because of the difficulty of finding target antigens that are not also expressed on vital normal tissues, and partly because the immunosuppressive tumor microenvironment can disable even engineered T cells. A related approach, tumor-infiltrating lymphocyte (TIL) therapy, involves isolating T cells from a patient's tumor, expanding the ones that recognize tumor antigens, and reinfusing them. This has shown promise in melanoma but is logistically complex and has not been widely generalized.
These approaches are not rival schools in the sense of mutually exclusive paradigms; they are complementary levels of analysis that increasingly converge. Immunoediting provides the temporal and conceptual framework within which the other approaches operate. Antigen discovery identifies the targets that T cells see. Tumor microenvironment research explains why seeing a target is not enough—why T cells that recognize tumor antigens often fail to act. Checkpoint biology identifies one major mechanism of that failure and provides a therapeutic lever. Adoptive cell therapy attempts to overcome the problem of insufficient or dysfunctional T cells by supplying new ones.
The convergence is visible in current research. Checkpoint blockade is now being combined with adoptive cell therapy, on the logic that engineered T cells will work better if the brakes on them are also released. Neoantigen discovery is being used to design personalized cancer vaccines, which aim to expand T cells against a patient's specific tumor mutations. Tumor microenvironment analysis is being used to identify which patients are likely to respond to checkpoint blockade—those with pre-existing T cell infiltration—and to develop strategies to convert cold tumors into hot ones.
The current landscape of tumor immunology is defined by both remarkable success and sobering limitation. Checkpoint inhibitors have cured a minority of patients with metastatic cancers that were previously almost uniformly fatal—a genuine breakthrough. But the majority of patients do not respond, and resistance can be primary (the tumor never responds) or acquired (the tumor initially responds and then progresses). Understanding and overcoming resistance is the field's central challenge.
Several themes dominate contemporary research. One is the role of the tumor's mutational burden: tumors with many mutations tend to generate more neoantigens and are more likely to respond to checkpoint blockade, but this correlation is imperfect, and the quality of neoantigens—how well they are presented and recognized—matters as much as their quantity. Another is the metabolic interplay between tumors and immune cells, as both compete for nutrients in a hostile microenvironment. A third is the gut microbiome, which has been reported to influence responses to checkpoint blockade, though the mechanisms and clinical significance remain actively debated. A fourth is the development of more sophisticated model systems, including patient-derived organoids and genetically engineered mice, to study tumor-immune interactions in ways that better recapitulate human disease.
The field also faces conceptual challenges. The immunoediting framework, while useful, is a simplification; not all tumors pass through all three phases, and the boundaries between them are blurry. The distinction between innate and adaptive immunity, while foundational, is increasingly recognized as porous, with innate immune cells such as macrophages and NK cells playing roles in both tumor rejection and tumor promotion. And the relationship between inflammation and cancer is double-edged: chronic inflammation can promote tumorigenesis, even as acute immune responses can destroy tumors.
Tumor immunology is thus a field in which the central questions remain open. The immune system can clearly be harnessed to fight cancer, and some patients are cured. But the field's ambition—to make immunotherapy work for the majority of patients, across the majority of cancer types—requires a deeper understanding of why the immune system so often fails, and how its failures might be systematically overcome. The field's history suggests that progress will come not from a single breakthrough but from the continued integration of its complementary approaches: understanding what the immune system sees, why it often does not act, and how it might be made to act anyway.